600222 Henan Taloph Pharmaceutical Stock
WatchlistHenan Taloph Pharmaceutical Stock News
Tailong Pharmaceutical (600222.SH): No antibiotics
Gelonghui November 28丨Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company has no antibiotics yet.
Tailong Pharmaceutical (600222.SH): Salvia salvia, a proprietary Chinese medicine product, has the effect of activating blood circulation and nourishing the heart
Gelonghui, November 22|Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company's proprietary Chinese medicine product salvia salvia oral liquid has the effects of activating blood circulation and nourishing the heart. Viburnum can nourish the heart, and nourish the stomach, and nourish the heart, all of which are drugs for the cardiovascular and cerebrovascular system.
Tailong Pharmaceutical (600222.SH): The controlling shareholder has not yet launched other major pharmaceutical and health management businesses
Gelonghui November 22|Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company's controlling shareholder has not yet carried out any other major pharmaceutical health business.
Tailong Pharmaceutical (600222.SH): The company's current daily production and operation activities are all normal
Gelonghui November 8 | Tailong Pharmaceutical (600222.SH) announced that the company's stock closed for three consecutive trading days on November 6, November 7, and November 8, 2023, with a cumulative deviation value of more than 20%. According to the relevant provisions of the “Shanghai Stock Exchange Trading Rules”, this is an abnormal fluctuation in stock trading. In the first three quarters of 2023, the company achieved operating income of 1,443 billion yuan, net profit attributable to shareholders of listed companies - 16.926,400 yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 23.875 million yuan, still remaining
Tailong Pharmaceutical (600222.SH): No cross-border export business involved
Gelonghui November 6 | Tailong Pharmaceutical (600222.SH) stated on the investor interactive platform that the company's products are mainly sold domestically and are not involved in cross-border export business for the time being.
Little Excitement Around Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Henan Taloph Pharmaceutical Stock Co.,Ltd (SHSE:600222) is definitely a stock worth checking out, seeing as almost half of all the Pha
Tailong Pharmaceutical (600222.SH) released the first three quarter results, with a net loss of 16.926,400 yuan
Tailong Pharmaceutical (600222.SH) released its report for the first three quarters of 2023, with revenue of 1,443 billion yuan,...
Tailong Pharmaceutical (600222.SH): Exclusive product, Shuanghuanglian Oral Liquid (children's type), is suitable for children aged 1-7
Glonghui, October 20, 丨 Tailong Pharmaceutical (600222.SH) said on the investor interactive platform that the company's exclusive product, Shuanghuanglian Oral Liquid (children type), is suitable for children aged 1-7; at the same time, the company also has children's medications such as pediatric compound chicken chewables, pediatric heat clearing and cough relief, and pediatric antipyretic oral liquid. Please refer to the drug instructions for use.
Tarong Pharmaceutical (600222.SH): Proposed to launch the fourth phase of the employee stock ownership plan
Glonghui, Oct. 17: Tailong Pharmaceutical (600222.SH) announced the fourth phase of the employee shareholding plan. The maximum amount of self-financing for the current employee shareholding plan is 79.8 million yuan, with “shares” as the subscription unit. Each share is 1 yuan, and the maximum number of shares for the current employee shareholding plan is 79.8 million. The total number of people who intend to participate in this plan shall not exceed 120, including no more than 6 directors, supervisors and senior managers. After the establishment of the current employee shareholding plan, it is proposed to transfer the company's repurchased shares through methods permitted by laws and regulations such as non-transactional transfers. The total number of shares to be transferred shall not exceed 14,523,
Henan Taloph Pharma Receives 41 Million Yuan in Government Grants in Q3
Henan Taloph Pharmaceutical (SHA:600222) has received a total of 40.9 million yuan in government subsidies in the third quarter, according to a filing on Monday. The grants equate to 5.67% of its net
Tarong Pharmaceutical (600222.SH): Received a government subsidy of 4.09 million yuan
Glonghui, October 8, 丨 Tailong Pharmaceutical (600222.SH) announced that the company and its subsidiaries received a total of 4.09 million yuan in government grants from July 1, 2023 to September 30, 2023, accounting for 5.67% of the absolute value of the company's most recent audited net profit attributable to shareholders of listed companies.
Henan Taloph Pharmaceutical StockLtd (SHSE:600222) Shareholders Are Still up 21% Over 5 Years Despite Pulling Back 12% in the Past Week
It hasn't been the best quarter for Henan Taloph Pharmaceutical Stock Co.,Ltd (SHSE:600222) shareholders, since the share price has fallen 17% in that time. But at least the stock is up over the la
Interpretation of Tarong Pharmaceutical's 2023 Interim Report: Financial Data Draws Attention, Performance Raises Concerns
According to Tairong Pharmaceutical's 2023 interim report data, revenue for the reporting period was 993,909,739.60 yuan, an increase of 15.08% compared to 863,676,913.87 yuan in the same period last year. This indicates that the company has achieved a certain increase in revenue, but does this mean that the company's overall operating conditions are also improving? Let's take another look at the company's net worth situation. Net assets attributable to shareholders of listed companies at the end of the reporting period were $1,418,871,940.83, compared to $1,570,479,281.96 at the end of the previous year, a decrease of $1,570,479,281.96
Tarong Pharmaceutical (600222.SH) released semi-annual results, with a net loss of 38.33 million yuan
Tarong Pharmaceutical (600222.SH) disclosed the 2023 semi-annual report. The company achieved revenue of 9.94 during the reporting period...
Tailong Pharmaceutical (600222.SH): Wu Lan reduced company's shares by 11.42 million yuan in violation of regulations
On August 7, GLONGHUI | Tailong Pharmaceutical (600222.SH) announced that due to not fully understanding the relevant regulations, Ms. Wu Lan reduced her holdings of 2,000,000 shares of the company through centralized bidding transactions on August 3, 2023, through centralized bidding transactions, with a transaction price of 5.71 yuan/share, with a reduction amount of 11,420,000 yuan. The number of shares reduced accounted for 0.35% of the company's total share capital. Ms. Wu Lan did not register and announce the holdings reduction plan on the Shanghai Stock Exchange 15 trading days before the current holdings reduction, which is in violation of the previous stock price
Taloph Pharmaceutical Gets Nod to Amend License of Three Products
Henan Taloph Pharmaceutical (SHA:600222) received approval from the Henan Provincial Drug Administration of China to amend the drug production license of three products. The changes include labeling t
Tailong Pharmaceutical (600222.SH): Three pharmaceuticals, including Agastache Zhengzheng Gas Blend, were changed from contract production to in-house production
On July 20, GLONGHUI | Tailong Pharmaceutical (600222.SH) announced that it has recently received the “Pharmaceutical Production License” approved and issued by the Henan Drug Administration, agreeing that the company's Shengmai Drink (Dang Shanfang), Wutziyanzong Oral Liquid, and Agastache Zhengqi Gas Blend will be commissioned to Zhejiang Guoguang Biopharmaceutical Co., Ltd. to produce it on its own. The current change in the “Pharmaceutical Production License” mainly focuses on the change of three drugs, including Agastache Zhengqi Compounds, from commissioned production to in-house production, which will help the company improve capacity utilization, further improve product quality by relying on the company's herbal medicine base, and meet market demand. It will have a positive impact on the company's future operations
Tailong Pharmaceutical (600222.SH) made an estimated loss, with an estimated net loss of 35 million yuan to 40 million yuan for the half year
According to the Zhitong Finance App, Tailong Pharmaceutical (600222.SH) issued an advance loss announcement for the 2023 semi-annual results. It is expected to achieve net profit attributable to shareholders of listed companies of 40 million yuan to -35 million yuan for the half year 2023, and losses will occur. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be -42 million yuan to -37 million yuan in the half year of 2023. During the reporting period, the company's drug research and development service business increased investment in R&D personnel at research institutes in Chongqing, Zhengzhou and other places. Relevant production capacity has not yet been fully released. At the same time, in order to continue to improve the market
Tailong Pharmaceutical (600222.SH): Completed the repurchase at a cost of 797.24 million yuan and has actually repurchased 2.53% of the shares
On July 13, 2023, the company completed the repurchase of 145.23,300 shares, accounting for 2.53% of the company's total share capital. The maximum repurchase price was 5.99 yuan/share, the minimum repurchase price was 4.99 yuan/share, the average repurchase price was 5.49 yuan/share, and the total capital used was 797.24 million yuan (including transaction fees). 600222.SH
Tailong Pharmaceutical (600222.SH): Zhengzhou Longhua Pharmaceutical Industry Fund Partners Participate in Investment and Establishment of Sub-Funds
GLONGHUA, July 10丨Tailong Pharmaceutical (600222.SH) announced that recently, 14 parties, including Longhua Pharmaceutical Industry Fund and Chengdu Junqi Enterprise Management Consulting Partnership, jointly signed the “Chengdu Junrongkang Venture Capital Partnership Limited Partnership Agreement”. As limited partners, they pledged an investment share of 50 million yuan of Chengdu Junrongkang Venture Capital Partnership, accounting for 3.125% of the total size of Chengdu Junrongkang Fund of 1.6 billion yuan.